

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5333662

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	2	
CONVEYING PARTY DATA		
	Name	Execution Date
	ALKERMES, INC.	08/13/2015
RECEIVING PARTY DATA		
Name:	ALKERMES PHARMA IRELAND LIMITED	
Street Address:	CONNAUGHT HOUSE	
Internal Address:	1 BURLINGTON ROAD	
City:	DUBLIN 4	
State/Country:	IRELAND	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16043721
CORRESPONDENCE DATA		
Fax Number:	(857)300-4001	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	857-300-4003	
Email:	bostonpatent@lathropgage.com,dvincent@lathropgage.com,dpstein@lathropgage.com	
Correspondent Name:	BRIAN C. TRINQUE	
Address Line 1:	LATHROP GAGE LLP	
Address Line 2:	28 STATE STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02109	
ATTORNEY DOCKET NUMBER:	582018: ALT-024CON	
NAME OF SUBMITTER:	BRIAN C. TRINQUE, PH.D., ESQ.	
SIGNATURE:	/BRIAN C. TRINQUE/	
DATE SIGNED:	01/18/2019	
Total Attachments: 3		
source=582018-EXECUTED-COMPANY-ASSIGN-572570-1-18-19#page1.tif		
source=582018-EXECUTED-COMPANY-ASSIGN-572570-1-18-19#page2.tif		
source=582018-EXECUTED-COMPANY-ASSIGN-572570-1-18-19#page3.tif		

ASSIGNMENT

WHEREAS, Alkermes, Inc., a corporation having its principal place of business at 852 Winter Street, Waltham, Massachusetts 02451 is the owner by assignment of certain applications identified as:

CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE LAUROXIL IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA

U.S. Serial No.: 62/041,341, filed August 25, 2014

WHEREAS, Alkermes Pharma Ireland Limited, a corporation having its principal place of business at Connaught House, 1 Burlington Road, Dublin 4, Ireland, is desirous of acquiring all rights, title and interests in and to said invention, said applications, and in and to any and all Letters Patent which may be granted for or upon said invention and applications in the United States of America and all countries foreign thereto.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Alkermes, Inc. has sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said Alkermes Pharma Ireland Limited the full and exclusive right, title and interest, throughout the world, in, to and under the following:

(a) said invention as fully set forth and described in the specification prepared,

and executed by us preparatory to obtaining Letters Patent of the United States therefor;

(b) said applications;

(c) any and all refilings, divisions, continuations and continuations-in-part of said application;

(d) any and all Letters Patent of the United States of America which may issue from said application, refilings, divisions, continuations and continuations-in-part;

(e) any and all reissues and reexaminations of said Letters Patent of the United States of America;

(f) any and all applications for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;

(g) any and all refilings, divisions and continuations of said foreign-filed applications;

(h) all claims, causes of action and damages for past infringement, if any, of said application;

(i) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed applications, refilings, divisions and continuations; and

(j) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

Alkermes, Inc. further agree that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to Alkermes Pharma Ireland Limited or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

ALL of the above shall be held and enjoyed by the said Alkermes Pharma Ireland Limited for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

Alkermes, Inc.

Claire M. Vasios
Signature

Claire M. Vasios
Name

V.P. of Intellectual Property
Title

13-Aug-2015

STATE OF Massachusetts
COUNTY OF Middlesex: SS:

On this 13th day of August, 2015, before me personally appeared Claire M Vasias to me known to be the person described in and who executed the foregoing instrument as his free act and deed.

In witness whereof, I have hereunto set my hand and affixed my notarial seal the day and year last above written.

Cindy A. Sragg
Notary Public

My commission expires: 11-Mar-2016
(SEAL)



CINDY A. SRAGG
Notary Public
Commonwealth of Massachusetts
My Commission Expires
March 11, 2016

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS

Waltham, MA
Signed At (City/State)

CINDY SRAGG
Name

Cindy Sragg
Signature

13-Aug-2015
Date



CINDY A. SRAGG
Notary Public
Commonwealth of Massachusetts
My Commission Expires
March 11, 2016